期刊
JOURNAL OF NEUROIMMUNOLOGY
卷 356, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.jneuroim.2021.577599
关键词
-
COVID-19 vaccination is recommended for multiple sclerosis patients, although different types of vaccines may have varying impacts on their efficacy. It is important to carefully select vaccines for these patients, as some treatments may affect vaccine responses. Avoiding vaccines that could impact vaccine efficacy is crucial in treated patients.
COVID-19 vaccination is recommended for multiple sclerosis patients. Disease-modifying therapies can influence the safety and efficacy of COVID-19 vaccines. RNA, DNA, protein, and inactivated vaccines are likely safe for multiple sclerosis patients. A few incidences of central demyelination were reported with viral vector vaccines, but their benefits likely outweigh their risks if alternatives are unavailable. Live-attenuated vaccines should be avoided whenever possible in treated patients. Interferon-beta, glatiramer acetate, teriflunomide, fumarates, and natalizumab are not expected to impact vaccine efficacy, while cell-depleting agents (ocrelizumab, rituximab, ofatumumab, alemtuzumab, and cladribine) and sphingosine-1-phosphate modulators will likely attenuate vaccine responses. Coordinating vaccine timing with dosing regimens for some therapies may optimize vaccine efficacy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据